

Ioannis E Koutroubakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3723455/publications.pdf>

Version: 2024-02-01

216
papers

7,888
citations

53789

45
h-index

60616

81
g-index

219
all docs

219
docs citations

219
times ranked

7669
citing authors

#	ARTICLE	IF	CITATIONS
1	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 239-254.	1.3	577
2	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 211-222.	1.3	425
3	Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases#. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1545-1553.	1.9	373
4	Mean platelet volume: a useful marker of inflammatory bowel disease activity. <i>American Journal of Gastroenterology</i> , 2001, 96, 776-781.	0.4	279
5	Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 100-105.	1.9	259
6	Ischemic colitis: Clinical practice in diagnosis and treatment. <i>World Journal of Gastroenterology</i> , 2008, 14, 7302.	3.3	216
7	Phenotype at diagnosis predicts recurrence rates in Crohn's disease. <i>Gut</i> , 2005, 55, 1124-1130.	12.1	207
8	Allelic polymorphism in IL-1 β and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2008, 102, 379-383.	2.6	182
9	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1381-1392.	4.4	161
10	Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 712-719.	0.4	156
11	Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). <i>Clinical and Experimental Immunology</i> , 2007, 103, 391-396.	2.6	133
12	Prevalence of Anemia in Inflammatory Bowel Diseases in European Countries. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 936-945.	1.9	129
13	Impact of Obesity on the Management and Clinical Course of Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2857-2863.	1.9	129
14	Role of Appendicitis and Appendectomy in the Pathogenesis of Ulcerative Colitis: A Critical Review. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 277-286.	1.9	125
15	Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. <i>American Journal of Gastroenterology</i> , 2000, 95, 171-176.	0.4	124
16	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018, 67, 244-254.	12.1	108
17	Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 429-436.	1.3	106
18	Decreased Total and Corrected Antioxidant Capacity in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1433-1437.	2.3	96

#	ARTICLE	IF	CITATIONS
19	Role of angiogenesis in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 515-523.	1.9	95
20	Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 190-194.	0.4	91
21	Leptin, adiponectin, resistin, and ghrelin – Implications for inflammatory bowel disease. <i>Molecular Nutrition and Food Research</i> , 2008, 52, 855-866.	3.3	87
22	The spectrum of segmental colitis associated with diverticulosis. <i>International Journal of Colorectal Disease</i> , 2005, 20, 28-32.	2.2	82
23	Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease. <i>Gastroenterology</i> , 2011, 140, 425-434.e1.	1.3	82
24	Fecal Calprotectin in Assessing Inflammatory Bowel Disease Endoscopic Activity: a Diagnostic Accuracy Meta-analysis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 27, 299-306.	0.9	82
25	Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 1998, 43, 2507-2512.	2.3	81
26	Therapy Insight: vascular complications in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 266-272.	1.7	80
27	Multipotent role of platelets in inflammatory bowel diseases: A clinical approach. <i>World Journal of Gastroenterology</i> , 2014, 20, 3180.	3.3	74
28	Increased serum levels of YKL-40 in patients with inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2003, 18, 254-259.	2.2	72
29	Diagnosing anemia in inflammatory bowel disease: Beyond the established markers. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 381-391.	1.3	72
30	Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1442-1449.	1.9	72
31	Anti-Saccharomyces Cerevisiae Mannan Antibodies and Antineutrophil Cytoplasmic Autoantibodies in Greek Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 449-454.	0.4	70
32	Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 262-268.	1.6	68
33	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. <i>Gastroenterology</i> , 2021, 160, 1452-1460.e21.	1.3	68
34	Somatostatin for acute severe bleeding from portal hypertensive gastropathy. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 509-512.	1.6	64
35	Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1760-1766.	4.4	62
36	The Emerging Role of Adipocytokines as Inflammatory Mediators in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 847-855.	1.9	59

#	ARTICLE	IF	CITATIONS
37	Appendectomy, tonsillectomy, and risk of inflammatory bowel disease. <i>Diseases of the Colon and Rectum</i> , 1999, 42, 225-230.	1.3	57
38	Analysis of Hospital-Based Emergency Department Visits for Inflammatory Bowel Disease in the USA. <i>Digestive Diseases and Sciences</i> , 2016, 61, 389-399.	2.3	53
39	Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2000, 45, 2347-2351.	2.3	51
40	A case of sigmoid endometriosis difficult to differentiate from colon cancer. <i>BMC Gastroenterology</i> , 2003, 3, 18.	2.0	50
41	Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 295-300.	1.3	50
42	Serum Angiogenin in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1758-1762.	2.3	49
43	Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease—the Unmet Needs. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 758-765.	1.3	49
44	A Prospective Epidemiologic Study of Crohn's Disease in Heraklion, Crete Incidence over a 5-Year Period. <i>Scandinavian Journal of Gastroenterology</i> , 1996, 31, 599-603.	1.5	48
45	The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 789-794.	1.6	47
46	Genetic Risk Factors In Patients With Inflammatory Bowel Disease And Vascular Complications: Case-Control Study. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 410-415.	1.9	47
47	Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 283-288.	1.6	46
48	Thrombosis and inflammatory bowel disease-the role of genetic risk factors. <i>World Journal of Gastroenterology</i> , 2008, 14, 4440.	3.3	45
49	Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2327-2331.	2.3	44
50	Risk of Venous Thromboembolism in Patients with Inflammatory Bowel Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 461-468.	2.7	44
51	Hypercoagulable States in Patients with Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2004, 49, 854-858.	2.3	43
52	Serum laminin and collagen IV in inflammatory bowel disease. <i>Journal of Clinical Pathology</i> , 2003, 56, 817-820.	2.0	42
53	Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 865-871.	2.3	42
54	Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in <i>in vitro</i> studies. <i>Clinical and Experimental Immunology</i> , 2010, 162, 337-347.	2.6	41

#	ARTICLE	IF	CITATIONS
55	Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype. <i>American Journal of Gastroenterology</i> , 2017, 112, 1849-1858.	0.4	41
56	Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. <i>European Journal of Clinical Investigation</i> , 2006, 36, 127-132.	3.4	40
57	Increased expression of VEGF and CD146 in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2008, 40, 673-679.	0.9	40
58	Silent Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	40
59	Ileocecal Anastomosis Type Significantly Influences Long-Term Functional Status, Quality of Life, and Healthcare Utilization in Postoperative Crohn's Disease Patients Independent of Inflammation Recurrence. <i>American Journal of Gastroenterology</i> , 2018, 113, 576-583.	0.4	40
60	Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 1415-1419.	1.6	38
61	Elevated Thrombopoietin Serum Levels in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 3478-3481.	0.4	37
62	Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 421-425.	1.6	37
63	Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 912-916.	1.6	37
64	Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 814-819.	1.6	36
65	Ulcerative colitis associated with primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1953-1956.	2.3	35
66	Role of Thrombotic Vascular Risk Factors in Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2000, 18, 161-167.	1.9	35
67	Stimulating erythropoiesis in inflammatory bowel disease associated anemia. <i>World Journal of Gastroenterology</i> , 2007, 13, 4798.	3.3	35
68	Five-Year Period Prevalence and Characteristics of Anemia in a Large US Inflammatory Bowel Disease Cohort. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 638-643.	2.2	35
69	Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. <i>Annals of Gastroenterology</i> , 2011, 24, 108-114.	0.6	34
70	Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1383-1387.	1.6	33
71	Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1147-1152.	1.6	33
72	The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1587-1593.	1.9	33

#	ARTICLE	IF	CITATIONS
73	Quality of Sleep and Coexistent Psychopathology Have Significant Impact on Fatigue Burden in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 423-430.	2.2	33
74	Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1.	1.6	31
75	The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1380-1388.	1.9	31
76	Colonic tuberculosis mimicking Crohn's disease: case report. <i>BMC Gastroenterology</i> , 2002, 2, 10.	2.0	29
77	Soluble transferrin receptor-ferritin index is the most efficient marker for the diagnosis of iron deficiency anemia in patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E158-E159.	1.9	29
78	Inflammatory Bowel Disease [IBD] and Physical Activity: A Study on the Impact of Diagnosis on the Level of Exercise Amongst Patients With IBD. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 686-692.	1.3	29
79	Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3236-3245.	2.3	28
80	Role of scintigraphy in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2693.	3.3	28
81	Recent advances in the management of distal ulcerative colitis. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2010, 1, 43.	1.1	28
82	NOD2 insertion mutation in a cretan Crohn's disease population. <i>Gastroenterology</i> , 2003, 124, 272-273.	1.3	27
83	Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2665-2671.	1.9	27
84	Ulcerative colitis is as common in Crete as in northern Europe: a 5-year prospective study. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 893-8.	1.6	27
85	Unraveling the Mechanisms of Thrombosis in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 1325-1327.	0.4	26
86	Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2180-2188.	1.9	26
87	Epithelioid Granulomas Associate With Increased Severity and Progression of Crohn's Disease, Based on 6-Year Follow-Up. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 900-907.e1.	4.4	26
88	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 480-489.	1.3	26
89	Active Inflammatory Bowel Disease: Evaluation with ^{99m} Tc (V) DMSA Scintigraphy. <i>Radiology</i> , 2003, 229, 70-74.	7.3	25
90	The Cost of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 107-115.	1.9	24

#	ARTICLE	IF	CITATIONS
91	Genetic Risk Factors in Young Patients With Ischemic Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 907-911.	4.4	21
92	Opioid Analgesics Do Not Improve Abdominal Pain or Quality of Life in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2379-2387.	2.3	20
93	Disease Characteristics and Severity in Patients With Inflammatory Bowel Disease With Coexistent Diabetes Mellitus. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1436-1442.	1.9	20
94	Association between ulcerative colitis and systemic lupus erythematosus. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 437-440.	1.6	19
95	Prognostic Significance of the Detection of Peripheral Blood CEACAM5 mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 165-173.	7.0	19
96	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	1.8	19
97	Pancreatic Autoantibodies in Greek Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2330-2334.	2.3	18
98	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	8.1	18
99	Idiopathic fibrosing pancreatitis and Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 1021-1024.	1.6	16
100	A case of orbital myositis preceding the intestinal symptoms of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 349-350.	1.3	16
101	Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients: The Magnitude of the Problem Is Staggering. <i>American Journal of Gastroenterology</i> , 2008, 103, 2281-2283.	0.4	14
102	Active inflammatory bowel disease: head-to-head comparison between 99mTc-hexamethylpropylene amine oxime white blood cells and 99mTc(V)-dimercaptosuccinic acid scintigraphy. <i>Nuclear Medicine Communications</i> , 2008, 29, 27-32.	1.1	14
103	Role of Ghrelin and Insulin-like Growth Factor Binding Protein-3 in the Development of Osteoporosis in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, e60-e65.	2.2	14
104	Anal adenocarcinoma complicating chronic Crohn's disease. <i>International Journal of Surgery Case Reports</i> , 2015, 10, 201-203.	0.6	14
105	Multiyear Patterns of Serum Inflammatory Biomarkers and Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 100-105.	1.9	14
106	Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e181.	2.5	14
107	Spectrum of non-inflammatory bowel disease and non-infectious colitis. <i>World Journal of Gastroenterology</i> , 2008, 14, 7277.	3.3	14
108	Low plasma protein Z levels in patients with ischemic colitis. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1673-1676.	2.3	13

#	ARTICLE	IF	CITATIONS
109	Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2576-2582.	1.9	13
110	Delineation of Crohn's Disease Trajectories Using Change in Löfgren Index. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 476-482.	2.2	13
111	Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 187-191.	1.6	12
112	Is there any role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome?. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 364-371.	1.6	12
113	Treatment of oesophageal Crohn's disease with infliximab. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 431-432.	1.6	11
114	Antibodies Against Cyclic Citrullinated Peptide (CCP) in Inflammatory Bowel Disease Patients With or Without Arthritic Manifestations. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 504-505.	1.9	11
115	The relationship between coagulation state and inflammatory bowel disease: current understanding and clinical implications. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 479-488.	3.0	11
116	Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2729-2739.	2.3	11
117	Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency. <i>Advances in Therapy</i> , 2020, 37, 1960-2002.	2.9	11
118	Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 70-78.	1.9	11
119	Circulating soluble vascular adhesion protein 1 in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 405-408.	1.6	10
120	JAK2 V617F mutation is not involved in thromboembolism in IBD. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1606-1607.	1.9	10
121	New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E8-E9.	1.9	10
122	The Bone and Fat Connection in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2207-2217.	1.9	10
123	Peripheral Blood Eosinophilia and Long-term Severity in Pediatric-Onset Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1890-1900.	1.9	10
124	Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1998, 30, 421-5.	0.5	10
125	Resistin: another rising biomarker in inflammatory bowel disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 1035-1037.	1.6	9
126	Correlation of anemia status with worsening bowel damage as measured by Löfgren Index in patients with Crohn's disease. <i>Digestive and Liver Disease</i> , 2016, 48, 626-631.	0.9	9

#	ARTICLE	IF	CITATIONS
127	Low bone mineral density in Greek patients with inflammatory bowel disease: prevalence and risk factors. <i>Annals of Gastroenterology</i> , 2011, 24, 41-46.	0.6	9
128	Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 105-10.	1.6	9
129	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	4.4	9
130	Assaying of Tumor Necrosis Factor α , Complement Factors, and α -1-Antitrypsin in the Diagnosis of Malignant Serous Effusions. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 562-565.	1.3	8
131	Small bowel perforation due to non-Hodgkin-lymphoma in a patient with ulcerative colitis and systemic lupus erythematosus. <i>Digestive and Liver Disease</i> , 2008, 40, 144.	0.9	8
132	Disseminated tuberculosis in a Crohn's disease patient on anti-TNF α therapy despite chemoprophylaxis. <i>Gut</i> , 2008, 57, 425-425.	12.1	8
133	Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1266-1271.	1.9	8
134	Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 773-776.	1.6	8
135	The burden and management of anemia in Greek patients with inflammatory bowel disease: a retrospective, multicenter, observational study. <i>BMC Gastroenterology</i> , 2021, 21, 269.	2.0	8
136	Immunogenetics of Cytokines: Relevance for Future Research on Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 1995, 30, 1139-1146.	1.5	7
137	Anti-TNF and Fistulising Perianal Crohns Disease: Use in Clinical Practice. <i>Current Drug Targets</i> , 2010, 11, 187-197.	2.1	7
138	Antiglycan Antibodies in Greek Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2011, 56, 845-852.	2.3	7
139	European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 802-806.	1.6	7
140	Mean platelet volume: a useful marker of inflammatory bowel disease activity. <i>American Journal of Gastroenterology</i> , 2001, 96, 776-781.	0.4	7
141	Treatment of anaemia in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1273-1274.	3.7	6
142	Increased Fracture Risk Assessed by Fracture Risk Assessment Tool in Greek Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 216-221.	2.3	6
143	Use of vedolizumab in a patient with chronic and refractory pouchitis. <i>Annals of Gastroenterology</i> , 2018, 31, 379.	0.6	6
144	Is there a role for Tc-99m (V) DMSA scintigraphy in ischemic colitis?. <i>World Journal of Gastroenterology</i> , 2008, 14, 5432.	3.3	6

#	ARTICLE	IF	CITATIONS
145	Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 641.	2.4	6
146	Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?. <i>Intestinal Research</i> , 2021, 19, 461-467.	2.6	5
147	Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. <i>Annals of Gastroenterology</i> , 2015, 28, 417-25.	0.6	5
148	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 940-945.	1.3	5
149	Solid extraintestinal malignancies in patients with inflammatory bowel disease. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1956-1980.	2.0	5
150	The patient with persistent perianal fistulae. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 503-518.	2.4	4
151	Acute Generalized Exanthematous Pustulosis Induced by Azathioprine in a Patient With Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1005-1007.	0.4	4
152	Prevalence of thiopurine S-methyltransferase gene polymorphisms in patients with inflammatory bowel disease from the island of Crete, Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1284-1289.	1.6	4
153	Clinical Characteristics of Inflammatory Bowel Disease Patients Requiring Long-term Parenteral Support in the Present Era of Highly Effective Biologic Therapy. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, 45, 1100-1107.	2.6	4
154	Keeping on the High Quality of Health Care in Greek Inflammatory Bowel Disease Patients in the SARS-CoV-2 Era. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2380-2381.	4.4	4
155	The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 581-587.	1.6	4
156	Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 228-237.	1.9	4
157	Anti- <i>Saccharomyces cerevisiae</i> mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 449-454.	0.4	3
158	Acquired and hereditary thrombotic risk factors in patients with acute mesenteric vein thrombosis. <i>American Journal of Gastroenterology</i> , 2002, 97, 768-769.	0.4	3
159	^{99m} Tc-Leucoscan in the evaluation of inflammatory bowel disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1098-1098.	6.4	3
160	Sa1144 Association Between Surgical Anastomotic Technique and Postoperative Healthcare Financial Burden in Patients With Crohn's Disease: A Longterm, Prospective Study. <i>Gastroenterology</i> , 2015, 148, S-239.	1.3	3
161	Telephone Encounters Predict Future High Financial Expenditures in Inflammatory Bowel Disease Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 319-325.	2.2	3
162	Elevated thrombopoietin serum levels in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 3478-3481.	0.4	3

#	ARTICLE	IF	CITATIONS
163	Distinct features of circulating microparticles and their relationship with disease activity in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2016, 29, 180-7.	0.6	3
164	Eosinophilic gastroenteritis associated with Churg-Strauss syndrome. <i>Annals of Gastroenterology</i> , 2012, 25, 164.	0.6	3
165	Inherited Thrombophilia and Thrombosis in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2006, 101, 403-403.	0.4	2
166	Which patients with IBD are at risk of venous thromboembolism?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 307-308.	17.8	2
167	Ulcerative colitis and Budd-Chiari syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1306.	1.6	2
168	Lymphangiogenesis in Inflammatory Bowel Disease; A New Therapeutic Target?. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e154.	2.5	2
169	IBD LIVE Case Series—Case 6. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2754-2764.	1.9	2
170	Comparison of the Uptake of Screening Colonoscopy between Physicians and the General Population in Greece. <i>Digestive Diseases</i> , 2020, 38, 23-30.	1.9	2
171	Mucocutaneous manifestations in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, 1387-1393.	1.6	2
172	Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. <i>American Journal of Gastroenterology</i> , 2000, 95, 171-176.	0.4	2
173	Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 190-194.	0.4	2
174	Hyperhomocysteinemia in greek patients with inflammatory bowel disease. <i>Gastroenterology</i> , 2000, 118, A314.	1.3	1
175	Serum laminin and collagen IV in patients with inflammatory bowel disease. <i>Gastroenterology</i> , 2003, 124, A202-A203.	1.3	1
176	Transient ischaemic colitis following an aeroplane flight. <i>Gut</i> , 2003, 52, 1072-a-1073.	12.1	1
177	Disease activity and venous thromboembolism in inflammatory bowel disease. <i>Lancet</i> , The, 2010, 375, 1689.	13.7	1
178	Cornelia de Lange syndrome in association with ulcerative colitis: A case report. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e399-e400.	1.3	1
179	Su1334 Eosinophilia in Patients With Inflammatory Bowel Disease Is Independently Associated With Increased Healthcare Expenditures: A Prospective 5-Year Experience. <i>Gastroenterology</i> , 2015, 148, S-477-S-478.	1.3	1
180	Su1810 Clostridium difficile Infection in Inflammatory Bowel Disease Predicts Future Healthcare Utilization. <i>Gastroenterology</i> , 2016, 150, S559.	1.3	1

#	ARTICLE	IF	CITATIONS
181	Tu1946 Can We Phenotype IBD Patients Based on Financial Charges Over Time? Trajectory Modeling of Healthcare Utilization in a Large, Prospective IBD Cohort. <i>Gastroenterology</i> , 2016, 150, S986-S987.	1.3	1
182	Sa1954 Sickest of the Sick: When Anti-TNF Agents Fail to Halt Progression of Bowel Damage in Crohn's Disease Over Time. <i>Gastroenterology</i> , 2016, 150, S415.	1.3	1
183	Sa1876 Do Epithelioid Granulomas Function As a Biomarker of Severity in Crohn's Disease? Analysis of a Prospective Six-Year Natural History Registry. <i>Gastroenterology</i> , 2016, 150, S387-S388.	1.3	1
184	Extra-pleural Solitary Fibrous Tumor of the Pelvis in a Patient with Crohn's Disease Under Anti-TNF: A Case Report. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e55-e56.	1.9	1
185	Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 295.	0.8	1
186	Osteoclast: like giant cell undifferentiated pancreatic tumor diagnosed by means of EUS guided FNA. <i>Acta Biomedica</i> , 2021, 92, e2021106.	0.3	1
187	Unraveling the mechanisms of thrombosis in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 1325-1327.	0.4	1
188	Hypercoagulable states in patients with hepatocellular carcinoma. <i>Gastroenterology</i> , 2003, 124, A563-A564.	1.3	0
189	Low plasma protein Z levels in patients with colon ischemia. <i>Gastroenterology</i> , 2003, 124, A189.	1.3	0
190	New imaging techniques: promise or passe. <i>Gut</i> , 2003, 52, 1072-1072.	12.1	0
191	Autoimmune pancreatitis. A rare cause of cholestasis. <i>Digestive and Liver Disease</i> , 2011, 43, e3.	0.9	0
192	The Janus Tyrosine Kinase-2 V617F Mutation is Not Implicated in the Pathogenesis of Ischemic Colitis in Young Patients. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 433-434.	2.2	0
193	Advances in the Management of Inflammatory Bowel Disease. , 2013, , .		0
194	Reply to Polyzos and Kountouras. <i>Inflammatory Bowel Diseases</i> , 2014, 20, E22-E23.	1.9	0
195	Routine Measurement of Quality of Life in Inflammatory Bowel Disease Predicts Future Health Outcomes. <i>American Journal of Gastroenterology</i> , 2016, 111, S270.	0.4	0
196	162 Investigating the Effect of Granulomatous Inflammation on Bowel Damage in Patients With Crohn's Disease: A Natural History Study. <i>Gastroenterology</i> , 2016, 150, S41.	1.3	0
197	1123 Investigating the Changes in Atherosclerotic Cardiovascular Risk Profile of IBD Patients Over 6 Years. <i>Gastroenterology</i> , 2016, 150, S226.	1.3	0
198	Response to van den Heuvel et al.. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1374-1374.	1.3	0

#	ARTICLE	IF	CITATIONS
199	Tu1932 Long Term Implications of Achieving and Retaining Remission in Crohn's Disease as Defined by Harvey Bradshaw Index. <i>Gastroenterology</i> , 2016, 150, S981.	1.3	0
200	Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel. <i>Gastroenterology</i> , 2016, 150, S991.	1.3	0
201	Poor Consumption of Fiber, not fat, is Associated with Active Disease in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 152, S365.	1.3	0
202	Is High Globulin Fraction a Biomarker of Severity in Inflammatory Bowel Disease (IBD)? Analysis of a 6-Year, Prospective Natural History Registry. <i>Gastroenterology</i> , 2017, 152, S372.	1.3	0
203	Variation in Annual Rate of Steroid Prescriptions Amongst Providers for Inflammatory Bowel Disease Patients is Dependent on Cohort Size and Disease Severity. <i>Gastroenterology</i> , 2017, 152, S792.	1.3	0
204	Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1037-1038.	3.7	0
205	Letter to the Editor: Is There a Role for Switching Infliximab in Order to Regain Anti-TNF Response in Cases With Active Inflammatory Bowel Disease?. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e120-e120.	1.9	0
206	Risk Factors of Colectomy in Patients With Refractory Ulcerative Colitis Under Calcineurin Inhibitors Combined With Vedolizumab. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1213-1214.	4.4	0
207	Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e50.	1.9	0
208	Reply to the letter to the Editor: "The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease". <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 300-302.	1.6	0
209	Peripheral Blood Eosinophilia as a Potential Marker of Bowel Damage Progression in Crohn's Disease a 5 Year Natural History Study. <i>American Journal of Gastroenterology</i> , 2016, 111, S287.	0.4	0
210	Comparative Effectiveness of Common Immunomodulator Agents over 5 Year Clinical Outcomes in Crohn's Disease Patients. <i>American Journal of Gastroenterology</i> , 2016, 111, S293-S294.	0.4	0
211	Reply - Fecal calprotectin correlates well with endoscopic activity in ulcerative colitis patients. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018, 27, 474-475.	0.9	0
212	Pyoderma gangrenosum associated with chronic refractory pouchitis: a case successfully treated with infliximab. <i>Annals of Gastroenterology</i> , 2020, 33, 433-435.	0.6	0
213	New Editorial Board - a new start. <i>Annals of Gastroenterology</i> , 2011, 24, 8.	0.6	0
214	Gastric non-Hodgkin's lymphoma. <i>Annals of Gastroenterology</i> , 2014, 27, 167.	0.6	0
215	Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2022, 37, 639-646.	2.2	0
216	Acquired and hereditary thrombotic risk factors in patients with acute mesenteric vein thrombosis. <i>American Journal of Gastroenterology</i> , 2002, 97, 768-769.	0.4	0